Inhibitor of Apoptosis (IAP) proteins as therapeutic targets for radiosensitization of human cancers

Cancer Treatment Reviews

Volumn 38, Issue 6, 2012, Pages 760-766

  Fulda, Simone ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; IAP proteins; Radiotherapy; Smac

Indexed keywords

AEG 35156; AEG 40826; ANTINEOPLASTIC AGENT; AT 406; GD 0917; GDC 0917; HGS 1029; INHIBITOR OF APOPTOSIS PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN INHIBITOR; LCL 161; LDL 161; PROTEIN INHIBITOR; TL 32711; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DEATH; DNA DAMAGE; DRUG TARGETING; HUMAN; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RADIOSENSITIVITY; RADIOSENSITIZATION; REVIEW; SIGNAL TRANSDUCTION;

CELL DEATH; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; GENE EXPRESSION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASMS; PROTEIN BINDING; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION;

EID: 84861703831     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.01.005     Document Type: Review

References (64)

1. Lockshin R.A., Zakeri Z. Cell death in health and disease. J Cell Mol Med 2007, 11:1214-1224.
2. Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009, 124:511-515.
3. Schmidt-Ullrich R.K., Dent P., Grant S., Mikkelsen R.B., Valerie K. Signal transduction and cellular radiation responses. Radiat Res 2000, 153:245-257.
4. Roos W.P., Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006, 12:440-450.
5. Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci 2007, 96:2181-2196.
6. Kolesnick R., Fuks Z. Radiation and ceramide-induced apoptosis. Oncogene 2003, 22:5897-5906.
7. Chen Q., Chai Y.C., Mazumder S., et al. The late increase in intracellular free radical oxygen species during apoptosis is associated with cytochrome c release, caspase activation, and mitochondrial dysfunction. Cell Death Differ 2003, 10:323-334.
8. Dent P., Yacoub A., Fisher P.B., Hagan M.P., Grant S. MAPK pathways in radiation responses. Oncogene 2003, 22:5885-5896.
9. Gong B., Chen Q., Endlich B., Mazumder S., Almasan A. Ionizing radiation-induced, Bax-mediated cell death is dependent on activation of cysteine and serine proteases. Cell Growth Differ 1999, 10:491-502.
10. Taylor R.C., Cullen S.P., Martin S.J. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008, 9:231-241.
11. Chen Q., Gong B., Almasan A. Distinct stages of cytochrome c release from mitochondria: evidence for a feedback amplification loop linking caspase activation to mitochondrial dysfunction in genotoxic stress induced apoptosis. Cell Death Differ 2000, 7:227-233.
12. Fulda S., Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811.
13. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 2008, 19:325-331.
14. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010, 9:447-464.
15. Fulda S., Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Disc 2012, 11:109-124.
16. Vucic D., Dixit V.M., Wertz I.E. Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol 2011, 12:439-452.
17. Eckelman B.P., Salvesen G.S., Scott F.L. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 2006, 7:988-994.
18. Lu M., Lin S.-C., Huang Y., et al. XIAP induces NF-kappaB activation via the BIR1/TAB1 interaction and BIR1 dimerization. Mol Cell 2007, 26:689-702.
19. Hofer-Warbinek R., Schmid J.A., Stehlik C., Binder B.R., Lipp J., de Martin R. Activation of NF-kappa B by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. J Biol Chem 2000, 275:22064-22068.
20. Varfolomeev E., Vucic D. (Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways. Cell Cycle 2008, 7:1511-1521.
21. Lewis S.M., Holcik M. IRES in distress: translational regulation of the inhibitor of apoptosis proteins XIAP and HIAP2 during cell stress. Cell Death Differ 2005, 12:547-553.
22. Holcik M., Lefebvre C., Yeh C., Chow T., Korneluk R.G. A new internal-ribosome-entry-site motif potentiates XIAP-mediated cytoprotection. Nat Cell Biol 1999, 1:190-192.
23. Warnakulasuriyarachchi D., Ungureanu N.H., Holcik M. The translation of an antiapoptotic protein HIAP2 is regulated by an upstream open reading frame. Cell Death Differ 2003, 10:899-904.
24. Holcik M., Yeh C., Korneluk R.G., Chow T. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene 2000, 19:4174-4177.
25. Gu L., Zhu N., Zhang H., Durden D.L., Feng Y., Zhou M. Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell 2009, 15:363-375.
26. Tamm I. AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer. Curr Opin Investig Drugs 2008, 9:638-646.
27. Mannhold R., Fulda S., Carosati E. IAP antagonists: promising candidates for cancer therapy. Drug Discov Today 2010, 15:210-219.
28. Straub C.S. Targeting IAPs as an approach to anti-cancer therapy. Curr Top Med Chem 2011, 11:291-316.
29. Chai J., Du C., Wu J.W., Kyin S., Wang X., Shi Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 2000, 406:855-862.
30. Giagkousiklidis S., Vogler M., Westhoff M.A., Kasperczyk H., Debatin K.M., Fulda S. Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. Cancer Res 2005, 65:10502-10513.
31. Fandy T.E., Shankar S., Srivastava R.K. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol Cancer 2008, 7:60.
32. Giagkousiklidis S., Vellanki S.H., Debatin K.M., Fulda S. Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition. Oncogene 2007, 26:7006-7016.
33. Kim D.W., Seo S.W., Cho S.K., et al. Targeting of cell survival genes using small interfering RNAs (siRNAs) enhances radiosensitivity of Grade II chondrosarcoma cells. J Orthop Res 2007, 25:820-828.
34. Wang R., Li B., Wang X., et al. Inhibiting XIAP expression by RNAi to inhibit proliferation and enhance radiosensitivity in laryngeal cancer cell line. Auris Nasus Larynx 2009, 36:332-339.
35. Connolly K., Mitter R., Muir M., Jodrell D., Guichard S. Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro. Cancer Chemother Pharmacol 2009, 64:307-316.
36. Ohnishi K., Scuric Z., Schiestl R.H., Okamoto N., Takahashi A., Ohnishi T. SiRNA targeting NBS1 or XIAP increases radiation sensitivity of human cancer cells independent of TP53 status. Radiat Res 2006, 166:454-462.
37. Ohnishi K., Nagata Y., Takahashi A., Taniguchi S., Ohnishi T. Effective enhancement of X-ray-induced apoptosis in human cancer cells with mutated p53 by siRNA targeting XIAP. Oncol Rep 2008, 20:57-61.
38. Vellanki S.H., Grabrucker A., Liebau S., et al. Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia 2009, 11:743-752.
39. Bao S., Wu Q., McLendon R.E., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
40. Berger R., Jennewein C., Marschall V., et al. NF-{kappa}B is required for Smac mimetic-mediated sensitization of glioblastoma cells for {gamma}-irradiation-induced apoptosis. Mol Cancer Ther 2011, 10:1867-1875.
41. Li W., Li B., Giacalone N.J., et al. BV6, an IAP antagonist, activates apoptosis and enhances radiosensitization of non-small cell lung carcinoma in vitro. J Thorac Oncol 2011, 6:1801-1809.
42. Ziegler D.S., Keating J., Kesari S., et al. A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo. Neuro Oncol 2011, 13:820-829.
43. Yang D., Zhao Y., Li A.Y., Wang S., Wang G., Sun Y. Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis. Breast Cancer Res Treat 2011, [Sep 7, e-pub ahead of print].
44. Yang J., McEachern D., Li W., et al. Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases. Mol Cancer Ther 2011, 10:658-669.
45. Dai Y., Liu M., Tang W., et al. Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. Clin Cancer Res 2008, 14:7701-7710.
46. Huerta S., Gao X., Livingston E.H., Kapur P., Sun H., Anthony T. In vitro and in vivo radiosensitization of colorectal cancer HT-29 cells by the smac mimetic JP-1201. Surgery 2010, 148:346-353.
47. Karikari C.A., Roy I., Tryggestad E., et al. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol Cancer Ther 2007, 6:957-966.
48. Cao C., Mu Y., Hallahan D.E., Lu B. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 2004, 23:7047-7052.
49. Ahn K.S., Sethi G., Aggarwal B.B. Embelin, an inhibitor of X chromosome-linked inhibitor-of-apoptosis protein, blocks nuclear factor-kappaB (NF-kappaB) signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Mol Pharmacol 2007, 71:209-219.
50. Nikolovska-Coleska Z., Xu L., Hu Z., et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem 2004, 47:2430-2440.
51. Dai Y., Desano J., Qu Y., et al. Natural IAP inhibitor Embelin enhances therapeutic efficacy of ionizing radiation in prostate cancer. Am J Cancer Res 2011, 1:128-143.
52. Hinz M., Stilmann M., Arslan S.C., Khanna K.K., Dittmar G., Scheidereit C. A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-kappaB activation. Mol Cell 2010, 40:63-74.
53. Li F., Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 2010, 1805:167-180.
54. Tenev T., Bianchi K., Darding M., et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 2011, 43:432-448.
55. Loeder S., Fakler M., Schoeneberger H., et al. RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. Leukemia 2011, [E-pub ahead of print].
56. Schimmer A.D., Estey E.H., Borthakur G., et al. PhaseI/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol 2009, 27:4741-4746.
57. Schimmer A.D., Herr W., Hanel M., et al. Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study. Clin Lymphoma Myeloma Leukemia 2011, 11:433-438.
58. Genentech I. A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients with Refractory Solid Tumors or Lymphoma. Clinical Trials.gov. 2010.
59. Infante JR, Dees EC, Burris HA, et al. A phase I study of LCL-161, an oral inhibitor, in patients with advanced cancer. The Annual Meeting of the American Association for Cancer Research, Washington, DC, USA, 2010.
60. Cai Q., Sun H., Peng Y., et al. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem 2011, 54:2714-2726.
61. Amaravadi RK, Schilder RJ, Dy GK, et al. Phase I study of the Smac mimetic TL32711 in adult subjects with advanced solid tumors & lymphoma to evaluate safety, pharmocokinetics, pharmocodynamics and anti-tumor activity. 2011 Annual AACR conference, Orlando, FL, 2011.
62. Sikic BI, Eckhardt SG, Gallant G, et al. Safety, pharmocokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP), in patients (Pts.) with advanced solid tumors: Results of a Phase I study. 2011 Annual ASCO Meeting, Chicago, IL, 2011.
63. Ogura A., Watanabe Y., Iizuka D., et al. Radiation-induced apoptosis of tumor cells is facilitated by inhibition of the interaction between Survivin and Smac/DIABLO. Cancer Lett 2008, 259:71-81.
64. Carter B.Z., Mak D.H., Morris S.J., et al. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis 2011, 16:67-74.